Revenio's iCare DRSplus included in FDA-cleared AI solution for diabetic retinopathy screening

Revenio's iCare DRSplus fundus imaging system is now part of the first FDA-cleared AI screening solution for diabetic retinopathy in the United States, enabling automatic detection and referral for further examination in primary care settings.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.